Economic and humanistic burden of chronic liver diseases in the United States
Year: 2026
Type: article
Study design: Observational Study
Abstract: Little is known about the healthcare burden of Chronic liver disease (CLD) post-introduction of newer antiviral therapies for hepatitis. Therefore, this national study examined healthcare expenditures, productivity loss, and health-related quality of life (HRQoL) of patients with CLD. This retrospective, cross-sectional analysis utilized the 2014–2021 Medical Expenditure Panel Survey involving patients with CLD ≥18 years. Two-part model was employed to estimate incremental direct medical costs. Multivariable models were used to evaluate missed workdays and HRQoL. Annually, 1.63 million patients (95%CI=1.47–1.81) were diagnosed with CLD, with a prevalence of 0.59%. The mean annual incremental healthcare expenditure attributable to CLD was $11,711 (95%CI=$6,867.048–$16,555.36). Patients with CLD have 0.12 (95%CI=0.09–0.15) more missed workdays, translating into a national productivity loss of $51.6 million. Additionally, HRQoL was significantly lower in CLD patients, with mean differences of −3.72 (95%CI = −4.6 to -2.84) for physical component summary score and −1.83 (95%CI = −2.68 to −0.97) fore mental component summary score. CLD was associated with a significant healthcare burden, as evidenced by healthcare expenditure, productivity loss, and HRQoL. Therefore, concerted efforts are needed to improve the prevention and management of CLD to reduce the disease burden.
Source: Figshare
Subfield: Economics and Econometrics
Domain: Social Sciences
Open Access status: green
OpenAlex ID: W7130356307
FWCI:
Cites:
Cited by:
Related to: